CPT code 0565T represents an autologous procedure that harvests a patient’s fat tissue, processes it into a cellular implant, and prepares it for injection into the patient’s knee joint. The code captures a combined service focused on biologic preparation and intended intra-articular administration. Nationally, this code is relevant as interest in cell-based orthobiologic therapies and their distinct billing pathways has grown, raising questions about coverage policy, coding clarity, and clinical evidence standards.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on the clinical context of the procedure, typical sites of service, and how the code is used in practice. The publication also summarizes available benchmarks for utilization and reimbursement, outlines common documentation and coding considerations, and highlights recent policy developments that affect coverage and payment for autologous cellular knee implant procedures. This resource is intended to inform payers, providers, and policy analysts about coding application, service characterization, and the issues shaping reimbursement and access for this emerging orthobiologic service.